Quan Jing Wang·2025-04-17 06:16Core Viewpoint - The company emphasizes balancing retained earnings for acquisitions and shareholder returns, with a focus on enhancing market confidence through share buybacks and increased dividends [2][3]. Financial Performance - In 2024, the company reported revenue of 1.659 billion RMB, a decrease of 4.75% year-on-year, while net profit reached 533 million RMB, an increase of 1.70% [12]. - Total assets grew to 5.575 billion RMB, up 7.71% from the previous year, and equity attributable to shareholders increased by 11.11% to 4.139 billion RMB [12]. Strategic Partnerships - The collaboration with China National Pharmaceutical Group (Sinopharm) has led to significant growth in procurement contracts, customer numbers, and product varieties [3][5]. - The company is leveraging Sinopharm's resources to enhance its market presence and operational synergy [3][5]. Market Challenges and Strategies - The IVD industry faces challenges due to intensified competition and price reductions from centralized procurement, with reagent prices dropping by 50-80% [4][11]. - The company plans to maintain its market position through marketing-driven strategies, refined management, and diversification [4][11]. Innovation and R&D - The company is focusing on expanding its product lines across various fields, including biochemistry, pathology, and immunology, while increasing R&D investments [9][10]. - AI technology is being integrated into pathology diagnostics, with ongoing collaborations with leading universities to enhance diagnostic efficiency and accuracy [6][19]. Export and International Market - The company's export business has seen a 36.57% increase in 2024, with a strong competitive edge in the immunohistochemistry sector [16][13]. - The company has established a research center with Xiamen University to develop AI-assisted diagnostic systems, indicating a commitment to innovation in the international market [19].